Ferroportin disease is a rare type of autosomal dominantly inherited 
hemochromatosis caused with mutations in the ferroportin gene (SLC40A1). The 
patients characteristically have hyperferritinemia but normal transferin 
saturations. Herein, we present a 15-year-old female whose chief complaint was 
persistent nausea for the last one year. Extensive work-up including brain 
imaging revealed nothing to explain the etiology of nausea. The serum ferritin 
level of 1474ng/mL was suggestive for hemochromatosis syndromes and the 
molecular testing revealed de-novo c.485_487delTTG (P.Val162del) ferroportin 
gene mutation. Mild hepatic iron loading, in addition to the cumbersome nausea 
were accepted as indications for chelation treatment in this particular patient 
and deferasirox was initiated (10mg/kg/day) since family did not consent for 
phlebotomy. Deferasirox was stopped by the 9th month of initiation, since nausea 
subsided and hepatic iron content was normalized, in order to prevent over 
chelation. There are no well-established guidelines for the chelation of 
patients with hereditary hemochromatosis syndromes. However, lifelong 
monitorization for iron loading and re-initiation of chelation when necessary 
was planned in our patient.